期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

提高乳腺癌患者内分泌治疗服药依从性的深度访谈 被引量：13

Challenges of medication compliance to hormonal therapy for breast cancer patients: In-depth interview of health care professionals
下载PDF
导出
摘要 目的探讨接受内分泌治疗的乳腺癌患者服药依从性的现状及对策。方法采用关键知情人访谈法,对15名医务人员开展个人深入访谈。结果乳腺癌患者术后辅助内分泌治疗服药依从性不佳的行为多样,中断服药是主要表现形式。未来要提高乳腺癌患者内分泌治疗的服药依从性,亟待个体化、持续跟进的随访模式。结论在未来的护理实践和研究中,建议个体化、持续跟进的措施,改善乳腺癌患者内分泌治疗的服药依从性。 Objective To study current situation and countermeasure of the medication compliance to hormonal therapy for breast cancer patients. Method In-depth interviews were conducted among 15 health care professionals u- sing key insider interviews. Result The results of in-depth interviews showed that discontinuation was the most com- mon manifestation of low medication co and sustained interventions to improve mplian the m ce for breast cancer patients. It is pretty urgent to study individualized edication compliance to hormonal therapy for breast cancer patients. Conclusion It is recommended that customized and sustained interventions should be implored to improve the medica tion compliance to hormonal therapy for breast cancer patients.
作者 朱叶卉 胡雁 吴密彬 陆箴琦 黄嘉玲 裘佳佳
机构地区 复旦大学护理学院 复旦大学附属肿瘤医院
出处 《护士进修杂志》 2014年第7期594-598,共5页 Journal of Nurses Training
基金 2012年上海市卫生局局级科研项目(编号:2012-96) 复旦大学护理科研项目(编号:FNSF201102)
关键词 乳腺癌 内分泌治疗 依从性 质性研究 Breast cancer Hormonal therapy Compliance Qualitative study
分类号 R473.73 [医药卫生—护理学] R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Jemal A, Bray F, Center M M, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2) : 69-90.
  • 2中华人民共和国卫生部.中国卫生部卫生统计年鉴[EB/0L].http://www, moh. gov. cn/publicfiles/business/htmlfiles/ zwgkzt/ptjnj/year2010/index2010, html, 2012-9-14.
  • 3宋三秦,张少华.乳腺癌内分泌治疗的基本药物和新动向[J].实用肿瘤学杂志,2010,24(4):301-304. 被引量：4
  • 4NCCN. National Comprehensive Cancer Network Clinical Prac- tice Guidelines in Oncology, Breast Cancer[EB/OL]. http://www. nccn. org/professionals/physician_gls/f_guidelines, asp breast,2012-9-14.
  • 5Sanders C. Application of Colaizzi' S method: interpretation of an auditable decision trail by a novice researcher[J]. Contemp Nurse, 2003, 14(3): 292-302.
  • 6Vogel B A, Bengel J, Helmes A W. Information and decision making., patients needs and experiences in the course of breast cancer treatmentl[J]. Patient Educ Couns, 2008,71 ( 1 ) : 79-85.
  • 7Wolf L. The information needs of women who have undergone breast reconstruction. Part I, decision-making and sources of information[J]. Eur J Oncol Nurs, 2004, 8(3) : 211-223.
  • 8Sabate E. Adherence to long-tirm therapies Evidence for ac- tion[M]. World Health Organization,2003.
  • 9Mills M E, Sullivan K. The importance of information giving for patients newly diagnosed with cancer: a review of the liter- ature[J]. J Clin Nurs, 1999,8 (15) : 631-642.

二级参考文献21

  • 1Buzdar A,Douma J,Davidson N,et al.Phase III,multicenter,double blind,randomized study of letrozole,an aromatase inhibitor,for advanced breast cancer versus megestrol acetate[J].J Clin Oncol.2001,19(23):3357-3366.
  • 2Buzdar AU,Jonat W,Howell A,et al.Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma:results of a survival update based on a combined analysis of data from two mature phase III trials.Arimidex Study Group[J].Cancer.1998,83(6):1142-1152.
  • 3Bonneter re J,Thurlimann B,Robertson JF,et al.Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study[J].J Clin Oncol.2000,18(22):3748-3757.
  • 4Nabholtz JM,Buzdar A,Pollak M,et al.Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:results of a North American multicenter randomized trial.Arimidex Study Group[J].J Clin Oncol.2000,18(22):3758-3767.
  • 5Vergote I,Bonneterre J,Thurlimann B,et al.Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women[J].Eur J Cancer.2000,36(suppl 4):84-85.
  • 6Chia S,Gradishar W,Mauriac L,et al.Double-blind,randomized placebo controlled trial of fulvestrant compared with exemestane after priornonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive,advanced breast cancer:results from EFECT[J].J Clin Oncol.2008,26(10):1664-1670.
  • 7Ellis MJ,Ma C.Letrozole in the neoadjuvant setting:the P024 trial[J].Breast Cancer Res Treat.2007,105(Suppl 1):33-43.
  • 8Early Breast Cancer Trialists' Collaborative Group.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials[J].Lancet.2005,365(9472):1687-1717.
  • 9Fisher B,Dignam J,Bryant J,et al.Five versus more than five years of tamoxifen for lymph node-negative breast cancer:updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial[J].J Natl Cancer Inst.2001,93(9):684-90.
  • 10Burdette-Radoux S,Muss HB.A question of duration:do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy[J].Clin Breast Cancer.2009,9(Suppl 1):S37-41.

共引文献3

同被引文献106

  • 1周达生,姚华庭.医学系统工程与遵医行为研究[J].中国医院管理,1995,15(2):37-39. 被引量：583
  • 2蔡雁,施晓群,金艳.乳腺癌患者术后乳房缺失心理体验的质性研究[J].中华护理杂志,2006,41(2):105-108. 被引量：204
  • 3文华,苏小茵,高玲玲.化疗期乳腺癌病人抑郁与自我效能的相关性研究[J].中华护理杂志,2007,42(4):322-324. 被引量：109
  • 4Morisky DE,Green LW,Levine DM.Concurrent and predictive validity of a self-reported measure of medication adherence [ J ].Med Care,1986,24(1):67-74.
  • 5Osterberg L,Blaschke T.Adherence to medication [ J ].N Engl J Med,2005,353(5):487-497.
  • 6Darkow T,Henk HJ,Thomas SK,et al.Treatment interruption and non-adherence with imatinib and associated healthcare costs:a ret-rospective analysis among managed care patients with chronic my-elogenous leukaemia [ J ].Pharmacoeconomics,2007,25(6):481-496.
  • 7Noens L,van Lierde MA,De Bock R,et al.Prevalence,determi-nants,and outcomes of nonadherence to imatinib therapy in pa-tients with chronic myeloid leukemia:the ADAGIO study [ J].Blood,2009,113(22):5401-5411.
  • 8Ghayad SE,VendreU JA,Ben Larbi S,et al.Endocrine resistance associated with activated ErbB system in breast cancer ceils is re-versed by inhibiting MAPK or P13 K/Akt signaling pathways [ J ].lnt J Cancer,2010,126(2):545-562.
  • 9Likhite VS,Stossi E,Kim K,et al.Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand,deoxvrihonucleic acid,and eoregulators associated with alterations in estrogen and tamoxifen activity [ J ].Mol Endocrinol,2006,20(12):3120-3132.
  • 10NCCN.National Comprehensive Cancer Network Clinical Practice Guiddines in Oncology,Breast Cancer [ EB/OL ].http://www.nccn.org/professionals/physician _ gls/f_ guidelines,asp # hrest,2012-9-14.

引证文献13

二级引证文献69

护士进修杂志
2014年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部